Enthera develops disease‑modifying biologics intended to transform treatment of specific autoimmune conditions by re‑establishing stem cell capabilities through a non‑traditional approach. Its discovery centers on the IGFBP3/TMEM219 pathway, which is implicated in beta cell and stem cell apoptosis in the pancreas and gut. The company is building a pipeline of inhibitory monoclonal antibodies and fusion proteins targeting that pathway. Its lead program, Ent001, is described as the only drug in development with the potential to restore the endogenous pancreatic beta cell compartment in type 1 diabetes and the original intestinal structure in inflammatory bowel disease to re‑establish organ function. Proceeds from the Series A will be used to obtain clinical proof‑of‑concept via a first‑in‑human study of Ent001 and to further develop Enthera’s pipeline. Enthera is headquartered in Milan, was founded in 2016 as a spin‑off of the BiovelocITA accelerator, and protects its discovery engine and assets with a broad portfolio of patents. Enthera is a Milan-based biotech developing first-in-class biologics that aim to re-establish stem cell capabilities in a non-traditional way. The company’s primary targets are type 1 diabetes (T1D) and inflammatory bowel disease (IBD). Its lead program, Ent001, targets the IGFBP3/TMEM219 pathway and is described as the only drug in development with potential to restore the pancreatic beta cell compartment in T1D and the original intestine structure in IBD. Enthera is building a pipeline of inhibitory monoclonal antibodies and fusion proteins directed at the pathway and holds a broad portfolio of patents. The €28 million Series A will be used to obtain clinical proof-of-concept through a first-in-human study of Ent001 and to further develop the wider pipeline. The company was founded in 2016 as the first spin-off of BiovelocITA and is backed by Sofinnova Partners and the JDRF T1D Fund.

Total raised

$75M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2021